附註:"April 2005."
Celliance adds serum-free hybri-cyte to product portfolio -- Vertex licenses VX-944 to Avalon for cancer treatment -- Provenge/Avastin impact PSA doubling time in prostate cancer -- Triage stroke panel PMA accepted for FDA review -- Biocryst completes BCX-4208 phase I trial for psoriasis.
